Nicoll AJ, et al. - Because mycophenolate mofetil, the most widely used second-line agent in the real-world setting, is a commonly used salvage therapy for autoimmune hepatitis (AIH) patients, researchers assessed predictors of mycophenolate rescue therapy response to facilitate clinical decision-making. The study sample consisted of AIH patients managed in 17 major Australian liver centres who received mycophenolate with/without thiopurine(s) after an inadequate response or intolerance to corticosteroids. According to this retrospective observational cohort study, mycophenolate remains an excellent treatment option for patients with AIH refractory or standard therapy intolerant who are most likely to benefit from older and/or lower levels of IgG pre-treatment. Effective treatment alternatives remain a high priority for patients who fail second-line therapy.